参考文献/References:
[1] Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012[J]. CA:Cancer J Clin, 2015, 65(2):87-108.
[2] Sun XP, Dong X, Lin L, et al. Up-regulation of survivin by AKT and hypoxia-inducible factor 1α contributes to cisplatin resistance in gastric cancer[J]. FEBS J, 2014, 281(1):115-128. DOI:10.1111/febs.12577.
[3] Spick C, Herrmann K, Czernin J. 18F-FDG PET/CT and PET/MRI Perform Equally Well in Cancer:Evidence from Studies on More Than 2300 Patients[J]. J Nucl Med, 2016, 57(3):420-430. DOI:10.2967/jnumed.115.158808.
[4] Wu CX, Zhu ZH. Diagnosis and evaluation of gastric cancer by positron emission tomography[J]. World J Gastroenterol, 2014, 20(16):4574-4585. DOI:10.3748/wjg.v20.i16.4574.
[5] Smyth E, Schöder H, Strong VE, et al. A prospective evaluation of the utility of 2-deoxy-2-[(18) F]fluoro-D-glucose positron emission tomography and computed tomography in staging locally advanced gastric cancer[J]. Cancer, 2012, 118(22):5481-5488. DOI:10.1002/cncr.27550.
[6] Yun M. Imaging of Gastric Cancer Metabolism Using 18F-FDG PET/CT[J]. J Gastric Cancer, 2014, 14(1):1-6. DOI:10.5230/jgc. 2014. 14.1.1.
[7] Redondo-Cerezo E, Martínez-Cara JG, Jiménez-Rosales R, et al. Endoscopic ultrasound in gastric cancer staging before and after neoadjuvant chemotherapy. A comparison with PET-CT in a clinical series[J]. United European Gastroenterol J, 2017, 5(5):641-647. DOI:10.1177/2050640616684697.
[8] Altini C, Niccoli AA, Di PA, et al. 18F-FDG PET/CT role in staging of gastric carcinomas:comparison with conventional contrast enhancement computed tomography[J/OL]. Medicine (Baltimore), 2015, 94(20):e864[2018-01-08]. https://www.ncbi.nlm.nih.gov/pubmed/25997066. DOI:10.1097/MD.0000000000000864.
[9] Ma Q, Xin J, Zhao Z, et al. Value of 18F-FDG PET/CT in the diagnosis of primary gastric cancer via stomach distension[J/OL]. Eur J Radiol, 2013, 82(6):e302-306[2018-01-08]. https://www.ncbi.nlm.nih.gov/pubmed/23434453. DOI:10.1016/j.ejrad.2013. 01. 021.
[10] Youn SH, Seo KW, Lee SH, et al. 18F-2-Deoxy-2-Fluoro-D-Glucose Positron Emission Tomography:Computed Tomography for Preoperative Staging in Gastric Cancer Patients[J]. J Gastric Cancer, 2012, 12(3):179-186. DOI:10.5230/jgc.2012.12.3.179.
[11] Minamimoto R, Senda M, Jinnouchi S, et al. Performance profile of a FDG-PET cancer screening program for detecting gastric cancer:results from a nationwide Japanese survey[J]. Jpn J Radiol, 2014, 32(5):253-259. DOI:10.1007/s11604-014-0294-0.
[12] Inoue K, Goto R, Okada K, et al. A bone marrow F-18 FDG uptake exceeding the liver uptake may indicate bone marrow hyperactivity[J]. Ann Nucl Med, 2009, 23(7):643-649. DOI:10.1007/s12149-009-0286-9.
[13] Lee SJ, Lee WW, Yoon HJ, et al. Regional PET/CT after water gastric inflation for evaluating loco-regional disease of gastric cancer[J]. Eur J Radiol, 2013, 82(6):935-942. DOI:10.1016/j.ejrad.2013.01.014.
[14] Kim SJ, Cho YS, Moon SH, et al. Primary Tumor 18F-FDG Avidity Affects the Performance of 18F-FDG PET/CT for Detecting Gastric Cancer Recurrence[J]. J Nucl Med, 2016, 57(4):544-550. DOI:10.2967/jnumed.115.163295.
[15] Jemal A, Bray F, Center MM, et al. Global cancer statistics[J]. CA:Cancer J Clin, 2011, 61(2):69-90.
[16] Na SJ, o JH, Park JM, et al. Prognostic value of metabolic parameters on preoperative 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with stageⅢ gastric cancer[J]. Oncotarget, 2016, 7(39):63968-63980. DOI:10.18632/oncotarget.11574.
[17] Kaneko Y, Murray WK, Link E, et al. Improving patient selection for 18F-FDG PET scanning in the staging of gastric cancer[J]. J Nucl Med, 2015, 56(4):523-529. DOI:10.2967/jnumed.114.150946.
[18] Ha TK, Choi YY, Song SY, et al. F18-fluorodeoxyglucose-positron emission tomography and computed tomography is not accurate in preoperative staging of gastric cancer[J]. J Korean Surg Soc, 2011, 81(2):104-110. DOI:10.4174/jkss.2011.81.2.104.
[19] Yoon NR, Park JM, Jung HS, et al.[Usefulness of 18F-fluoro-2-deoxyglucose positron emission tomography in evaluation of gastric cancer stage] [J]. Korean J Gastroenterol, 2012, 59(5):347-353.
[20] Stabile IAA, Telegrafo M, Lucarelli NM, et al. Comparison between CT Net enhancement and PET/CT SUV for N staging of gastric cancer:A case series[J/OL]. Ann Med Surg (Lond), 2017, 21:1-6[2018-01-07]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5519227. DOI:10.1016/j.amsu.2017.07.033.
[21] Choi JI, Joo I, Lee JM. State-of-the-art preoperative staging of gastric cancer by MDCT and magnetic resonance imaging[J]. World J Gastroenterol, 2014, 20(16):4546-4557. DOI:10.3748/wjg.v20.i16. 4546.
[22] Okumura Y, Aikou S, Onoyama H, et al. Evaluation of 18F-FDG uptake for detecting lymph node metastasis of gastric cancer:a prospective pilot study for one-to-one comparison of radiation dose and pathological findings[J/OL]. World J Surg Oncol, 2015, 13:327[2018-01-07]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4667411. DOI:10.1186/s12957-015-0743-y.
[23] Oh HH, Lee SE, Choi IS, et al. The peak-standardized uptake value (P-SUV) by preoperative positron emission tomography-computed tomography (PET-CT) is a useful indicator of lymph node metastasis in gastric cancer[J]. J Surg Oncol, 2011, 104(5):530-533. DOI:10.1002/jso.21985.
[24] Wang Z, Chen JQ. Imaging in assessing hepatic and peritoneal metastases of gastric cancer:a systematic review[J]. BMC Gastroenterol, 2011, 11:19. DOI:10.1186/1471-230X-11-19.
[25] Kawanaka Y, Kitajima K, Fukushima K, et al. Added value of pretreatment 18F-FDG PET/CT for staging of advanced gastric cancer:Comparison with contrast-enhanced MDCT[J]. Eur J Radiol, 2016, 85(5):989-995. DOI:10.1016/j.ejrad.2016.03.003.
[26] Choi JY, Shim KN, Kim SE, et al. The clinical value of 18F-fluorodeoxyglucose uptake on positron emission tomography/computed tomography for predicting regional lymph node metastasis and non-curative surgery in primary gastric carcinoma[J]. Korean J Gastroenterol, 2014, 64(6):340-347.
[27] Kim DW, Park SA, Kim CG. Detecting the recurrence of gastric cancer after curative resection:comparison of FDG PET/CT and contrast-enhanced abdominal CT[J]. J Korean Med Sci, 2011, 26(7):875-880. DOI:10.3346/jkms.2011.26.7.875.
[28] Ma DW, Kim JH, Jeon TJ, et al. 18F-fluorodeoxyglucose positron emission tomography-computed tomography for the evaluation of bone metastasis in patients with gastric cancer[J]. Dig Liver Dis, 2013, 45(9):769-775. DOI:10.1016/j.dld.2013.02.009.
[29] Lee JH, Son SY, Lee CM, et al. Factors predicting peritoneal recurrence in advanced gastric cancer:implication for adjuvant intraperitoneal chemotherapy[J]. Gastric Cancer, 2014, 17(3):529-536. DOI:10.1007/s10120-013-0306-2.
[30] Kang WM, Meng QB, Yu JC, et al. Factors associated with early recurrence after curative surgery for gastric cancer[J]. World J Gastroenterol, 2015, 21(19):5934-5940. DOI:10.3748/wjg.v21.i19. 5934.
[31] Lee JW, Lee SM, Son MW, et al. Diagnostic performance of FDG PET/CT for surveillance in asymptomatic gastric cancer patients after curative surgical resection[J]. Eur J Nucl Med Mol Imaging, 2016, 43(5):881-888. DOI:10.1007/s00259-015-3249-5.
[32] Wu LM, Hu JN, Hua J, et al. 18F-fluorodeoxyglucose positron emission tomography to evaluate recurrent gastric cancer:a systematic review and meta-analysis[J]. J Gastroenterol Hepatol, 2012, 27(3):472-480. DOI:10.1111/j.1440-1746.2011.06919.x.
[33] Lee JW, Lee SM, Lee MS, et al. Role of 18F-FDG PET/CT in the prediction of gastric cancer recurrence after curative surgical resection[J]. Eur J Nucl Med Mol Imaging, 2012, 39(9):1425-1434. DOI:10.1007/s00259-012-2164-2.
[34] Sharma P, Singh H, Suman SK, et al. 18F-FDG PET-CT for detecting recurrent gastric adenocarcinoma:results from a Non-Oriental Asian population[J]. Nucl Med Commun, 2012, 33(9):960-966. DOI:10.1097/MNM.0b013e328355b694.
[35] Zou H, Zhao Y. 18FDG PET-CT for detecting gastric cancer recurrence after surgical resection:a meta-analysis[J]. Surg Oncol, 2013, 22(3):162-166. DOI:10.1016/j.suronc.2013.05.001.
[36] Lee DY, Lee CH, Seo MJ, et al. Performance of 18F-FDG PET/CT as a postoperative surveillance imaging modality for asymptomatic advanced gastric cancer patients[J]. Ann Nucl Med, 2014, 28(8):789-795. DOI:10.1007/s12149-014-0871-4.
[37] Choi BW, Zeon SK, Kim SH, et al. Significance of SUV on Follow-up 18F FDG PET at the Anastomotic Site of Gastroduodenostomy after Distal Subtotal Gastrectomy in Patients with Gastric Cancer[J]. Nucl Med Mol Imaging, 2011, 45(4):285-290. DOI:10.1007/s13139-011-0105-9.
[38] Karimi P, Islami F, Anandasabapathy S, et al. Gastric cancer:descriptive epidemiology, risk factors, screening, and prevention[J]. Cancer Epidemiol Biomarkers Prev, 2014, 23(5):700-713. DOI:10.1158/1055-9965.EPI-13-1057.
[39] Takahashi T, Saikawa Y, Kitagawa Y. Gastric cancer:current status of diagnosis and treatment[J]. Cancers (Basel), 2013, 5(1):48-63. DOI:10.3390/cancers5010048.
[40] Lee JW, Jo K, Cho A, et al. Relationship Between 18F-FDG Uptake on PET and Recurrence Patterns After Curative Surgical Resection in Patients with Advanced Gastric Cancer[J]. J Nucl Med, 2015, 56(10):1494-1500. DOI:10.2967/jnumed.115.160580.
[41] Sun X, Wang J, Liu J, et al. Albumin concentrations plus neutrophil lymphocyte ratios for predicting overall survival after curative resection for gastric cancer[J/OL]. Onco Targets Ther, 2016, 9:4661-4669[2018-01-07]. https://www.ncbi.nlm.nih/gov/pmc/articles/PMC4973773. DOI:10.2147/OTT.S108631.
[42] Grabinska K, Pelak M, Wydmanski J, et al. Prognostic value and clinical correlations of 18-fluorodeoxyglucose metabolism quantifiers in gastric cancer[J]. World J Gastroenterol, 2015, 21(19):5901-5909. DOI:10.3748/wjg.v21.i19.5901.
[43] Ock CY, Kim TY, Lee KH, et al. Metabolic landscape of advanced gastric cancer according to HER2 and its prognostic implications[J]. Gastric Cancer, 2016, 19(2):421-430. DOI:10.1007/s10120-015-0504-1.
[44] Wu Z, Zhao J, Gao P, et al. Prognostic value of pretreatment standardized uptake value of F-18-fluorodeoxyglucose PET in patients with gastric cancer:a meta-analysis[J]. BMC Cancer, 2017, 17(1):275. DOI:10.1186/s12885-017-3271-z.
[45] Park JS, Lee N, Beom SH, et al. The prognostic value of volume-based parameters using 18F-FDG PET/CT in gastric cancer according to HER2 status[J]. Gastric Cancer, 2018, 21(2):213-224. DOI:10.1007/s10120-017-0739-0.
[46] Coupe NA, Karikios D, Chong S, et al. Metabolic information on staging FDG-PET-CT as a prognostic tool in the evaluation of 97 patients with gastric cancer[J]. Ann Nucl Med, 2014, 28(2):128-135. DOI:10.1007/s12149-013-0791-8.
[47] Song BI, Kim HW, Won KS, et al. Preoperative Standardized Uptake Value of Metastatic Lymph Nodes Measured by 18F-FDG PET/CT Improves the Prediction of Prognosis in Gastric Cancer[J/OL]. Medicine (Baltimore), 2015, 94(26):e1037[2018-01-07]. https://www.ncbi.nlm.nih.gov/pubmed/26131811. DOI:10.1097/MD.0000000000001037.
相似文献/References:
[1]李生栩,唐明灯,林端瑜,等.18F-FDG SPECT-CT诊断胃癌术后复发及转移的价值[J].国际放射医学核医学杂志,2011,35(5):269.[doi:10.3760/cma.j.issn.1673-4114.2011.05.004]
LI Sheng-xu,TANG Ming-deng,LIN Duan-yu,et al.The value of 18F-FDG SPECT-CT in detecting recurrence and metastasis of gastric carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(6):269.[doi:10.3760/cma.j.issn.1673-4114.2011.05.004]
[2]濮伟刚,谭纪伏,朱建华,等.血浆中四种肿瘤标志物和13C-尿素呼气试验对胃癌诊断的对比研究[J].国际放射医学核医学杂志,2010,34(2):94.[doi:10.3760/cma.j.issn.1673-4114.2010.02.008]
PU Wei-gang,TAN Ji-fu,ZHU Jian-hua,et al.Clinical application of four plasma tumor markers and 13C-urea breath test in diagnosis of patients with gastric carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(6):94.[doi:10.3760/cma.j.issn.1673-4114.2010.02.008]
[3]王志军,丛英珍,许祖闪,等.高场强MRI在胃癌术后复发诊断中的应用价值[J].国际放射医学核医学杂志,2010,34(6):370.[doi:10.3760/cma.j.issn.1673-4114,2010.06.014]
WANG Zhi-jun,CONG Ying-zhen,XU Zu-shan,et al.Application of high-field-strength magnetic resonance imaging to diagnose recurrent gastric carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(6):370.[doi:10.3760/cma.j.issn.1673-4114,2010.06.014]
[4]荆卫娟,杨永青.慢性萎缩性胃炎向胃癌转化时血清胃泌素和幽门螺杆菌的变化及其作用[J].国际放射医学核医学杂志,2009,33(6):341.[doi:10.3760/cma.j.issn.1673-4114.2009.06.006]
JING Wei-juan,YANG Yong-qing.The changing and us interaction of determining serum gastrin levels and helicobacter pylori test during chronic atrophic gastritis into gastric cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2009,33(6):341.[doi:10.3760/cma.j.issn.1673-4114.2009.06.006]
[5]苏福,王卫星,张红,等.胃癌132例核素骨显像结果分析[J].国际放射医学核医学杂志,2007,31(2):94.
SU fu,WANG Wei-xing,ZHANG Hong,et al.Clinical analyses of radionuclide bone imaging with 132 gastric cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2007,31(6):94.
[6]梁琰,杜娟,李展展,等.18F-FDG SPECT/CT显像与64排螺旋CT异机融合技术在胃癌诊断中的应用[J].国际放射医学核医学杂志,2017,41(6):385.[doi:10.3760/cma.j.issn.1673-4114.2017.06.002]
Liang Yan,Du Juan,Li Zhanzhan,et al.Benefits of using 18F-FDG SPECT/CT combined with the 64-multislice spiral CT in gastric cancer diagnosis[J].International Journal of Radiation Medicine and Nuclear Medicine,2017,41(6):385.[doi:10.3760/cma.j.issn.1673-4114.2017.06.002]
[7]朱娅华,邓玮玮,范敏,等.18F-FDG PET/CT显像在胃癌分期及治疗方案制定中的应用价值[J].国际放射医学核医学杂志,2018,(1):15.[doi:10.3760/cma.j.issn.1673-4114.2018.01.003]
Zhu Yahua,Deng Weiwei,Fan Min,et al.Value of 18F-FDG PET/CT imaging on the staging of gastric carcinoma and its influence on therapeutic schedule formulation[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(6):15.[doi:10.3760/cma.j.issn.1673-4114.2018.01.003]
[8]陈挺,张宏,田梅.18F-FDG PET/CT代谢半定量参数在非小细胞肺癌预后评估中的价值[J].国际放射医学核医学杂志,2018,(3):269.[doi:10.3760/cma.j.issn.1673-4114.2018.03.014]
Chen Ting,Zhang Hong,Tian Mei.Prognostic evaluation of patients with non-small cell lung cancer by using semi-quantitative metabolic parameters of 18F-FDG PET/CT[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(6):269.[doi:10.3760/cma.j.issn.1673-4114.2018.03.014]
[9]杜芬,胡珊,梁梦,等.18F-FDG PET/CT显像在甲状腺偶发瘤良恶性诊断中的研究进展[J].国际放射医学核医学杂志,2018,(3):274.[doi:10.3760/cma.j.issn.1673-4114.2018.03.015]
Du Fen,Hu Shan,Liang Meng,et al.Development in the diagnosis of benign and malignant thyroid incidentalomas by 18F-FDG PET/CT imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(6):274.[doi:10.3760/cma.j.issn.1673-4114.2018.03.015]
[10]高之晔,韩星敏.放射性核素标记的胆碱在PET/CT肿瘤显像中的应用[J].国际放射医学核医学杂志,2018,(3):280.[doi:10.3760/cma.j.issn.1673-4114.2018.03.016]
Gao Zhiye,Han Xingmin.Application of radionuclide-labeled choline in PET/CT tumor imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(6):280.[doi:10.3760/cma.j.issn.1673-4114.2018.03.016]